The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Experimental therapies for sepsis directed against tumour necrosis factor

Experimental therapies for sepsis directed against tumour necrosis factor
Experimental therapies for sepsis directed against tumour necrosis factor

Tumour necrosis factor (TNF) has been identified as an important mediator involved in the generation of sepsis syndrome. Two major strategies have evolved for counteracting the effects of TNF in patients with severe manifestations of sepsis: neutralization by anti-TNF antibodies and competitive antagonism of TNF with synthetic soluble TNF receptors. Clinical trials with murine monoclonal antibodies against TNF have shown that this agent is able to reduce early morbidity and mortality, but with no reduction in 28 day mortality. A clinical study with a synthetic 75 kDa soluble TNF receptor failed to show any benefit with this drug and indeed there was higher mortality at higher doses. Trials of a 55 kDa soluble TNF receptor are continuing and this drug is apparently safe. Drugs that modify TNF in vivo may be a useful component of future management of sepsis, either as monotherapy or as part of a combined strategy of immunomodulation.

Antibodies, Monoclonal, Humans, Immunotherapy, Receptors, Tumor Necrosis Factor, Sepsis, Tumor Necrosis Factor-alpha, Journal Article, Review
0305-7453
65-69
Read, R.C.
b5caca7b-0063-438a-b703-7ecbb6fc2b51
Read, R.C.
b5caca7b-0063-438a-b703-7ecbb6fc2b51

Read, R.C. (1998) Experimental therapies for sepsis directed against tumour necrosis factor. Journal of Antimicrobial Chemotherapy, 41 (Suppl A), 65-69. (doi:10.1093/jac/41.suppl_1.65).

Record type: Article

Abstract

Tumour necrosis factor (TNF) has been identified as an important mediator involved in the generation of sepsis syndrome. Two major strategies have evolved for counteracting the effects of TNF in patients with severe manifestations of sepsis: neutralization by anti-TNF antibodies and competitive antagonism of TNF with synthetic soluble TNF receptors. Clinical trials with murine monoclonal antibodies against TNF have shown that this agent is able to reduce early morbidity and mortality, but with no reduction in 28 day mortality. A clinical study with a synthetic 75 kDa soluble TNF receptor failed to show any benefit with this drug and indeed there was higher mortality at higher doses. Trials of a 55 kDa soluble TNF receptor are continuing and this drug is apparently safe. Drugs that modify TNF in vivo may be a useful component of future management of sepsis, either as monotherapy or as part of a combined strategy of immunomodulation.

This record has no associated files available for download.

More information

Published date: January 1998
Keywords: Antibodies, Monoclonal, Humans, Immunotherapy, Receptors, Tumor Necrosis Factor, Sepsis, Tumor Necrosis Factor-alpha, Journal Article, Review

Identifiers

Local EPrints ID: 417320
URI: http://eprints.soton.ac.uk/id/eprint/417320
ISSN: 0305-7453
PURE UUID: fd785e61-bc0f-4aa2-926b-28dee8d01edd
ORCID for R.C. Read: ORCID iD orcid.org/0000-0002-4297-6728

Catalogue record

Date deposited: 29 Jan 2018 17:30
Last modified: 10 Nov 2021 03:30

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×